HC Wainwright & Co. Reiterates Buy on Talaris Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Talaris Therapeutics (NASDAQ:TALS) with a Buy and maintains $12 price target.
Mastercard Is Long-Term Compounder Trading At Discount To Defensive Sectors, Analysts Say Post Q4 Beat
Raymond James analyst John Davis maintained Mastercard Inc (NYSE: MA) with an Outperform and ra
Why This BuzzFeed Analyst Remains Bearish After Stock Skyrockets On Meta Platforms, OpenAI Partnerships
After ripping higher by more than 150% on Thursday, the Buzzfeed Inc (NASDAQ: BZFD) rally continued on Friday with the stock up another 85% in afternoon trading.
Mobileye’s Deal Wins Signal More Such Success Backed By Demand For SuperVision, Contributing To Higher Margins & FCF, Analysts Say
Needham analyst Rajvindra Gill maintained Mobileye Global Inc (NASDAQ:MBLY) with a Buy and raised the price target from $43 to $45. Mobileye’s…
Morgan Stanly Thinks Sherwin-Williams Is Conservative About 2023 Guidance
Morgan Stanley analyst Vincent Andrews reiterated an Overweight rating on the shares of Sherwin-Williams Co (NYSE:SHW) and lowered the price target from…
Rockwell Automation To See Healthy Orders Ducking The Demand Destruction Trend, Says Morgan Stanley
Morgan Stanley analyst Joshua Pokrzywinski reiterated an Overweight rating on the shares of Rockwell Automation Inc (NYSE:ROK) and raised the price target…
4 Intel Analysts React To ‘Historic Collapse’ In Q4 As Investors Head For Exits
Intel Corporation (NASDAQ: INTC) reported lower-than-expected results for the fourth quarter Thursday, with revenue of $14.042 billion, down 8% quarter-over-quarter.
Needham Reiterates Buy on Fair Isaac, Raises Price Target to $780
Needham analyst Kyle Peterson reiterates Fair Isaac (NYSE:FICO) with a Buy and raises the price target from $630 to $780.
HC Wainwright & Co. Reiterates Buy on Vericel, Maintains $37 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Vericel (NASDAQ:VCEL) with a Buy and maintains $37 price target.
HC Wainwright & Co. Reiterates Buy on Evotec, Maintains $12 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Evotec (NASDAQ:EVO) with a Buy and maintains $12 price target.